Everything you need to win Ethyreal — in one platform.
Who to reach, what to say, and why now on Ethyreal — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on Ethyreal — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
The decision-maker’s email and mobile — dial in-browser.
Ethyreal raises $101M to address Graves' disease and thyroid eye disease, backed by Atlas Venture and Medicxi.
PRIVATEJun 10, 2026•5 days ago
Amount Raised
$101 Million
BiotechnologyHealth Care
Investors
MedicxiAtlas Venture
Description
Ethyreal, a biotech company, has secured $101 million in funding to tackle the autoimmune conditions Graves' disease and thyroid eye disease. The funding round was led by Atlas Venture and Medicxi. This significant investment aims to advance treatments for these related health issues. The company was officially launched on Wednesday morning.
Company Information
Company
Ethyreal
About
Ethyreal is a biotech company focused on developing treatments for autoimmune conditions, specifically Graves' disease and thyroid eye disease. The company has recently secured significant funding to accelerate its research and development efforts. Backed by prominent investors, Ethyreal aims to address unmet medical needs in this area.
